|
|
生物标志物在神经内分泌肿瘤的表达及临床意义
|
Abstract:
神经内分泌肿瘤(Neuroendocrine neoplasms, NENs)是一种异质性神经内分泌系统肿瘤，其特点是惰性的生长速率和分泌多种肽激素和生物胺的能力。主要发生在消化道系统，且胃肠胰部位更加多见。目前，胃肠胰NENs (Gastroenteropancreatic-NENs, GEP-NENs)已成为消化系统第二类常见的癌症肿瘤。临床常用的CgA、Syn、CD56、NSE及Ki-67和新兴潜在SSTR2、INSM1和CD200的生物标记物的表达在诊断GEP-NENs方面被不断研究，但在疾病的预测、预后等方面仍有缺陷，随着神经内分泌肿瘤类型不断细化，迫切需要更加准确的生物标记物。因此，深入了解上述标记物与疾病的关系不仅对GEP-NENs的预测、诊断、治疗和预后有着深刻意义，而且为这些难治性肿瘤提供潜在治疗靶点。
Neuroendocrine neoplasms (NENs) are heterogeneous tumors of the neuroendocrine system characterized by inert growth rates and the ability to secrete multiple peptide hormones and biogenic amines. They occur mainly in the digestive system and are more common in gastroenteropancreatic sites. Currently, gastroenteropancreatic-NENs (GEP-NENs) have become the second most common type of cancerous tumors of the digestive system. The expression of clinically used biomarkers of CgA, Syn, CD56, NSE and Ki-67 and emerging potential SSTR2, INSM1 and CD200 have been continuously investigated in the diagnosis of GEP-NENs. However, they are still defective in the prediction of the disease, prognosis, etc. With the continuous refinement of neuroendocrine tumor types, there is an urgent need to continue with more accurate biomarkers. Therefore, an in-depth understanding of the relationship between the above markers and the disease is not only of profound significance for the prediction, diagnosis, treatment and prognosis of GEP-NENs, but also provides potential therapeutic targets for these refractory tumors.
| [1] | Cives, M. and Strosberg, J.R. (2018) Gastroenteropancreatic Neuroendocrine Tumors. CA: A Cancer Journal for Clinicians, 68, 471-487. https://doi.org/10.3322/caac.21493 |
| [2] | Das, S. and Dasari, A. (2021) Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Current Oncology Reports, 23, 43. |
| [3] | Pavel, M., Öberg, K., Falconi, M., Krenning, E.P., Sundin, A., Perren, A., et al. (2020) Gastroenteropancreatic Neuroendocrine Neoplasms: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 31, 844-860. https://doi.org/10.1016/j.annonc.2020.03.304 |
| [4] | Juhlin, C.C. (2021) Second-Generation Neuroendocrine Immunohistochemical Markers: Reflections from Clinical Implementation. Biology, 10, Article No. 874. https://doi.org/10.3390/biology10090874 |
| [5] | Laguerre, F., Anouar, Y. and Montero‐Hadjadje, M. (2019) Chromogranin a in the Early Steps of the Neurosecretory Pathway. IUBMB Life, 72, 524-532. https://doi.org/10.1002/iub.2218 |
| [6] | Paik, W. and Lee, K. (2022) Management of Small Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Current Opinion and Controversies. Journal of Clinical Medicine, 12, Article No. 251. https://doi.org/10.3390/jcm12010251 |
| [7] | Herrera-Martínez, A.D., Hofland, L.J., Gálvez Moreno, M.A., Castaño, J.P., de Herder, W.W. and Feelders, R.A. (2019) Neuroendocrine Neoplasms: Current and Potential Diagnostic, Predictive and Prognostic Markers. Endocrine-Related Cancer, 26, R157-R179. https://doi.org/10.1530/erc-18-0354 |
| [8] | 王舒敏, 俞飞, 王峰, 瞿卫. 血清嗜铬粒蛋白A测定在神经内分泌肿瘤诊断中的价值[J]. 国际检验医学杂志, 2022, 43(14): 1704-1708. |
| [9] | Dam, G., Grønbæk, H., Sorbye, H., Thiis Evensen, E., Paulsson, B., Sundin, A., et al. (2019) Prospective Study of Chromogranin a as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. Neuroendocrinology, 110, 217-224. https://doi.org/10.1159/000503833 |
| [10] | Kim, J., Kim, J.Y., Oh, E.H., Yoo, C., Park, I.J., Yang, D., et al. (2020) Chromogranin a Expression in Rectal Neuroendocrine Tumors Is Associated with More Aggressive Clinical Behavior and a Poorer Prognosis. American Journal of Surgical Pathology, 44, 1496-1505. https://doi.org/10.1097/pas.0000000000001526 |
| [11] | Tomita, T. (2020) Significance of Chromogranin A and Synaptophysin in Pancreatic Neuroendocrine Tumors. Biomolecules and Biomedicine, 20, 336-334. https://doi.org/10.17305/bjbms.2020.4632 |
| [12] | Fan, D., Li, X., Yu, Y., Wang, X., Fang, J. and Huang, C. (2023) Correlation between Clinicopathological Characteristics and the Clinical Prognosis of Patients with Gastroenteropancreatic Neuroendocrine Tumors. Molecular and Clinical Oncology, 19, Article No. 85. https://doi.org/10.3892/mco.2023.2681 |
| [13] | Uhlig, R., Dum, D., Gorbokon, N., Menz, A., Büscheck, F., Luebke, A.M., et al. (2022) Synaptophysin and Chromogranin a Expression Analysis in Human Tumors. Molecular and Cellular Endocrinology, 555, Article ID: 111726. https://doi.org/10.1016/j.mce.2022.111726 |
| [14] | Jacoba, I.M. and Weber, H.C. (2023) Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms. Current Opinion in Endocrinology, Diabetes & Obesity, 30, 175-180. https://doi.org/10.1097/med.0000000000000805 |
| [15] | Jian, Y., Zhang, L., Gong, L., Ding, M., Sun, X., Yu, X., et al. (2023) CD56 Polysialylation Promotes the Tumorigenesis and Progression via the Hedgehog and Wnt/β-Catenin Signaling Pathways in Clear Cell Renal Cell Carcinoma. Cancer Cell International, 23, Article No. 319. https://doi.org/10.1186/s12935-023-03165-5 |
| [16] | 李佳静, 常伟龙, 刘涛, 陈奎生, 张今, 孙淼淼. 胃肠道混合性神经内分泌-非神经内分泌肿瘤临床病理观察[J]. 肿瘤基础与临床, 2021, 34(2): 122-125. |
| [17] | 樊蕊蕊, 高杰, 路名芝. 低级别阑尾黏液性肿瘤伴肺胸膜转移碰撞阑尾神经内分泌肿瘤的临床病理分析[J]. 诊断病理学杂志, 2024, 31(8): 728-731. |
| [18] | Kečkéš, Š., Palaj, J., Waczulíková, I., Dyttert, D., Mojtová, E., Kováč, G., et al. (2021) Pretreatment Levels of Chromogranin a and Neuron-Specific Enolase in Patients with Gastroenteropancreatic Neuroendocrine Neoplasia. In Vivo, 35, 2863-2868. https://doi.org/10.21873/invivo.12574 |
| [19] | Mariën, L., Islam, O., Chhajlani, S., Lybaert, W., Peeters, M., Van Camp, G., et al. (2023) The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Perspective. Current Treatment Options in Oncology, 24, 1833-1851. https://doi.org/10.1007/s11864-023-01147-3 |
| [20] | Bellizzi, A.M. (2020) Immunohistochemistry in the Diagnosis and Classification of Neuroendocrine Neoplasms: What Can Brown Do for You? Human Pathology, 96, 8-33. https://doi.org/10.1016/j.humpath.2019.12.002 |
| [21] | Lopez-Aguiar, A.G., Ethun, C.G., Postlewait, L.M., Zhelnin, K., Krasinskas, A., El-Rayes, B.F., et al. (2017) Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease. Annals of Surgical Oncology, 25, 290-298. https://doi.org/10.1245/s10434-017-6140-8 |
| [22] | Ahn, B., Jung, J.K., Jung, H., Ryu, Y., Kim, Y.W., Song, T.J., et al. (2022) Double Ki-67 and Synaptophysin Labeling in Pancreatic Neuroendocrine Tumor Biopsies. Pancreatology, 22, 427-434. https://doi.org/10.1016/j.pan.2022.03.005 |
| [23] | Rorsman, P. and Huising, M.O. (2018) The Somatostatin-Secreting Pancreatic δ-Cell in Health and Disease. Nature Reviews Endocrinology, 14, 404-414. https://doi.org/10.1038/s41574-018-0020-6 |
| [24] | Alexander, E.S. and Ziv, E. (2023) Neuroendocrine Tumors: Genomics and Molecular Biomarkers with a Focus on Metastatic Disease. Cancers, 15, Article No. 2249. https://doi.org/10.3390/cancers15082249 |
| [25] | Harris, P.E. and Zhernosekov, K. (2022) The Evolution of PRRT for the Treatment of Neuroendocrine Tumors; What Comes Next? Frontiers in Endocrinology, 13, Article ID: 941832. https://doi.org/10.3389/fendo.2022.941832 |
| [26] | Kim, J.Y., Kim, J., Kim, Y., Yang, D., Yoo, C., Park, I.J., et al. (2024) Somatostatin Receptor 2 (SSTR2) Expression Is Associated with Better Clinical Outcome and Prognosis in Rectal Neuroendocrine Tumors. Scientific Reports, 14, Article No. 4047. https://doi.org/10.1038/s41598-024-54599-4 |
| [27] | Papotti, M., Bongiovanni, M., Volante, M., Allìa, E., Landolfi, S., Helboe, L., et al. (2002) Expression of Somatostatin Receptor Types 1-5 in 81 Cases of Gastrointestinal and Pancreatic Endocrine Tumors: A Correlative Immunohistochemical and Reverse-Transcriptase Polymerase Chain Reaction Analysis. Virchows Archiv, 440, 461-475. https://doi.org/10.1007/s00428-002-0609-x |
| [28] | Watanabe, H., Fujishima, F., Komoto, I., Imamura, M., Hijioka, S., Hara, K., et al. (2022) Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors. Cancers, 14, Article No. 775. https://doi.org/10.3390/cancers14030775 |
| [29] | Yu, J., Cao, F., Zhao, X., Xie, Q., Lu, M., Li, J., et al. (2021) Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-Dotatate Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms. Neuroendocrinology, 112, 358-369. https://doi.org/10.1159/000517530 |
| [30] | Chen, C., Notkins, A.L. and Lan, M.S. (2019) Insulinoma-Associated-1: From Neuroendocrine Tumor Marker to Cancer Therapeutics. Molecular Cancer Research, 17, 1597-1604. https://doi.org/10.1158/1541-7786.mcr-19-0286 |
| [31] | Zhang, Q., Huang, J., He, Y., Cao, R. and Shu, J. (2021) Insulinoma-Associated Protein 1 (INSM1) Is a Superior Marker for the Diagnosis of Gastroenteropancreatic Neuroendoerine Neoplasms: A Meta-Analysis. Endocrine, 74, 61-71. https://doi.org/10.1007/s12020-021-02754-6 |
| [32] | 王劲松, 王彬, 苟思琪, 杨路路, 齐琼, 黄文斌. INSM1在胃肠胰神经内分泌肿瘤诊断中的价值[J]. 临床与实验病理学杂志, 2019, 35(4): 407-411. |
| [33] | González, I., Lu, H., Sninsky, J., Yang, C., Bishnupuri, K., Dieckgraefe, B., et al. (2019) Insulinoma‐Associated Protein 1 Expression in Primary and Metastatic Neuroendocrine Neoplasms of the Gastrointestinal and Pancreaticobiliary Tracts. Histopathology, 75, 568-577. https://doi.org/10.1111/his.13899 |
| [34] | Xu, X., Wang, G., Duan, Y. and Huo, Z. (2022) Prognostic Value and Non-Neuroendocrine Role of INSM1 in Small Cell Lung Cancer. Pathology—Research and Practice, 229, Article ID: 153693. https://doi.org/10.1016/j.prp.2021.153693 |
| [35] | Nip, C., Wang, L. and Liu, C. (2023) CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy. Biomedicines, 11, Article No. 3326. https://doi.org/10.3390/biomedicines11123326 |
| [36] | Love, J.E., Thompson, K., Kilgore, M.R., Westerhoff, M., Murphy, C.E., Papanicolau-Sengos, A., et al. (2017) CD200 Expression in Neuroendocrine Neoplasms. American Journal of Clinical Pathology, 148, 236-242. https://doi.org/10.1093/ajcp/aqx071 |
| [37] | 都芳鹃, 宫媛, 张梅娟. INSM1、CD200、突触素在胰腺神经内分泌肿瘤诊断中的作用及实用性探讨[J]. 系统医学, 2023, 8(3): 16-19, 39. |
